Highline Wealth Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-26
Closed -$3.17K 1387
2025
Q4
$3.17K Hold
26
﹤0.01% 710
2025
Q3
$2.6K Buy
+26
New +$2.34K ﹤0.01% 801

Other funds holding XBI

Highline Wealth Partners's XBI Position: Q1 2026 in Review

Highline Wealth Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 26 shares — an estimated $3.17K sold.

Highline Wealth Partners first reported a position in XBI in Q3 2025 and held it in 2 quarters. The position peaked at $3.17K in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Highline Wealth Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Highline Wealth Partners sold 26 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.17K.
  • Highline Wealth Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 2 quarters.
  • Highline Wealth Partners's State Street SPDR S&P Biotech ETF position peaked at $3.17K in Q4 2025.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Highline Wealth Partners's 13F filing for Q1 2026, filed 6 Apr 2026.